血管閉塞危機市場分析及預測（至2035年）：依類型、產品類型、服務、技術、應用、最終使用者、設備、流程、解決方案分類

預計血管阻塞危象市場將從2024年的118億美元成長到2034年的240億美元，複合年成長率約為7.9%。此市場涵蓋鐮狀細胞疾病急性疼痛危機的治療，鐮狀細胞疾病是一種由鐮狀細胞血細胞引起的血流阻塞性鐮狀。市場包括藥物、疼痛管理療法和支持性護理解決方案。雖然人們對該疾病的認知不斷提高以及基因療法的進步正在拓展市場機遇，但以患者為中心的護理和新藥研發是推動市場成長的關鍵因素。主要趨勢包括個人化醫療和旨在改善患者預後和生活品質的創新藥物輸送系統。

血管阻塞危象市場預計將迎來顯著成長，主要驅動力來自治療性介入和病患管理策略的進步。藥物治療領域尤其突出，其中疾病修正治療因其改變疾病進展的潛力而發揮主導作用。儘管鎮痛藥，特別是鴉片類藥物，在急性疼痛管理中仍然發揮著重要作用，但由於其成癮性問題，其作用正受到越來越多的檢驗。非藥物療法，例如補液療法和輸血，作為輔助策略日益受到關注，這反映出人們越來越重視綜合護理方法。在新興治療方法中，基因療法和幹細胞移植有望徹底改變治療模式，提供長期解決方案並降低危機發生頻率。包括遠端醫療和病患監測應用程式在內的數位健康解決方案也正在蓬勃發展，有助於提高患者參與度和治療依從性。個人化醫療的整合可望進一步完善治療通訊協定，改善患者預後並提升市場表現。

血管閉塞性疾病市場的特點是市場佔有率分佈、定價策略和新產品發布都呈現動態變化。主要企業正透過創新產品和具競爭力的定價策略進行策略定位。醫學研究和技術的進步正推動新型治療方法和治療方案的快速成長。北美仍處於領先地位，擁有大量產品平臺等候核准。亞太和拉丁美洲等新興市場也展現出良好的成長潛力。競爭基準分析顯示，市場競爭異常激烈，多家主要企業爭奪主導。監管的影響至關重要，北美和歐洲嚴格的監管準則塑造市場動態。各公司正在加大合規投入並建立策略聯盟，以應對當前的監管環境。人們對有效治療方法的認知不斷提高，需求日益成長，這正在推動市場成長。儘管研發成本高昂和監管壁壘等挑戰依然存在，但對於那些願意創新和適應的公司而言，仍有許多成長機會。

主要趨勢和促進因素：

由於治療方法的進步和人們對鐮狀細胞疾病的認知不斷提高，血管阻塞危機 (VOC) 市場正在成長。一個關鍵趨勢是針對 VOC 根本原因的新型藥物的研發，這有望提高治療效果和改善患者預後。基因療法的整合也是一個重要趨勢，為 VOC 管理提供了潛在的長期解決方案。此外，遠端醫療和數位健康平台的擴展正在改善患者獲得治療和監測的機會，從而改善疾病管理。推動市場成長的一個因素是鐮狀細胞疾病在全球範圍內的盛行率不斷上升，尤其是在遺傳易感性高的地區。診斷能力的提高和早期篩檢計畫的發展也透過促進及時介入和治療，促進了市場成長。個人化醫療的推廣正在推動更有效、更個人化的 VOC 治療方案的發展。新興市場及其不斷發展的醫療基礎設施提供了眾多機會和市場擴張潛力。投資於創新治療方法和數位健康解決方案的公司將佔據有利地位，從而搶佔市場佔有率。隨著相關人員致力於提高病患的生活品質並降低與風險管理相關的醫療成本，VOC 市場蓄勢待發，即將迎來成長。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

• 宏觀經濟分析
• 市場趨勢
• 市場促進因素
• 市場機遇
• 市場限制
• 複合年均成長率：成長分析
• 影響分析
• 新興市場
• 技術藍圖
• 戰略框架

第4章 細分市場分析

• 市場規模及預測：依類型
  • 急性
  • 慢性的
• 市場規模及預測：依產品分類
  • 製藥
  • 生物製藥
  • 止痛藥
  • 羥基脲
  • L-麩醯胺酸
• 市場規模及預測：依服務分類
  • 病人支援服務
  • 諮詢服務
  • 遠端醫療
• 市場規模及預測：依技術分類
  • 基因治療
  • CRISPR技術
• 市場規模及預測：依應用領域分類
  • 疼痛管理
  • 輸血
• 市場規模及預測：依最終用戶分類
  • 醫院
  • 專科診所
  • 居家醫療環境
• 市場規模及預測：依設備分類
  • 點滴幫浦
  • 疼痛管理設備
• 市場規模及預測：依製程分類
  • 診斷
  • 治療
  • 監測
• 市場規模及預測：按解決方案分類
  • 綜合護理解決方案
  • 病患監測解決方案

第5章 區域分析

• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 其他拉丁美洲地區
• 亞太地區
  • 中國
  • 印度
  • 韓國
  • 日本
  • 澳洲
  • 台灣
  • 亞太其他地區
• 歐洲
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 義大利
  • 其他歐洲地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非
  • 撒哈拉以南非洲
  • 其他中東和非洲地區

第6章 市場策略

• 需求與供給差距分析
• 貿易和物流限制
• 價格、成本和利潤率趨勢
• 市場滲透率
• 消費者分析
• 法規概述

第7章 競爭訊息

• 市場定位
• 市場占有率
• 競爭基準
• 主要企業的策略

第8章 公司簡介

• Global Blood Therapeutics
• Emmaus Life Sciences
• Imara
• Forma Therapeutics
• Sancilio Pharmaceuticals
• Hema Care
• Glyco Mimetics
• Sickle Cell Disease Association of America
• Ar Qule
• Bioverativ
• CRISPR Therapeutics
• Editas Medicine
• Sangamo Therapeutics
• Bluebird Bio
• Novartis Institutes for Bio Medical Research
• Pfizer Rare Disease Consortium
• Mast Therapeutics
• Celgene Cellular Therapeutics
• Voyager Therapeutics
• Astraea Therapeutics

第9章：關於我們

Vaso Occlusive Crisis Market is anticipated to expand from $11.8 billion in 2024 to $24 billion by 2034, growing at a CAGR of approximately 7.9%. The Vaso Occlusive Crisis Market encompasses treatments for acute pain episodes in sickle cell disease, characterized by blocked blood flow due to sickled red blood cells. This market includes pharmaceuticals, pain management therapies, and supportive care solutions. Increased awareness and advancements in genetic therapies are expanding opportunities, while the focus on patient-centric care and novel drug development is driving growth. Key trends involve personalized medicine and innovative delivery systems aimed at improving patient outcomes and quality of life.

The Vaso Occlusive Crisis Market is poised for substantial growth, primarily driven by advancements in therapeutic interventions and patient management strategies. The pharmacological treatment segment stands out, with disease-modifying therapies leading the charge due to their potential to alter disease progression. Analgesics, particularly opioids, remain significant for acute pain management, though their role is increasingly scrutinized due to dependency concerns. Non-pharmacological treatments, such as hydration therapy and blood transfusions, are gaining attention as supplemental strategies, reflecting a growing emphasis on comprehensive care approaches. Among emerging therapies, gene therapy and stem cell transplants are anticipated to revolutionize treatment paradigms, offering long-term solutions and reducing crisis frequency. Digital health solutions, including telemedicine and patient monitoring apps, are also gaining momentum, enhancing patient engagement and adherence to treatment regimens. The integration of personalized medicine is expected to further refine treatment protocols, improving patient outcomes and market performance.

The Vaso Occlusive Crisis market is characterized by a dynamic landscape of market share distribution, pricing strategies, and new product launches. Key players are strategically positioning themselves through innovative offerings and competitive pricing. The market is witnessing a surge in novel therapies and treatment options, driven by advancements in medical research and technology. North America remains at the forefront, with a robust pipeline of products awaiting regulatory approval. Emerging markets in Asia-Pacific and Latin America are also showing promising growth potential. Competition benchmarking reveals a highly competitive environment with several key players vying for dominance. Regulatory influences play a critical role, with stringent guidelines in North America and Europe shaping market dynamics. Companies are investing in compliance and strategic partnerships to navigate these regulatory landscapes. The market is poised for growth, driven by increasing awareness and demand for effective treatments. Challenges such as high R&D costs and regulatory hurdles persist, but opportunities abound for those who innovate and adapt.

Geographical Overview:

The Vaso Occlusive Crisis market is witnessing notable regional variations, with distinct growth pockets emerging. North America stands at the forefront, propelled by advanced healthcare infrastructure and increased research funding. The region's focus on novel therapeutics and patient-centric care models enhances market potential. Europe follows closely, where strong regulatory frameworks and robust healthcare systems support market expansion. The European market benefits from strategic collaborations between pharmaceutical companies and research institutions. In Asia Pacific, rapid economic growth and increasing healthcare awareness drive market development. Countries like China and India are key players, investing heavily in healthcare innovation and infrastructure. Latin America and the Middle East & Africa are burgeoning markets with untapped potential. Brazil and South Africa, in particular, are recognizing the importance of addressing vaso-occlusive crises through improved healthcare access and innovative treatments. These regions are poised to experience growth as they prioritize healthcare advancements and strategic partnerships.

Global tariffs and geopolitical tensions significantly impact the Vaso Occlusive Crisis Market, with Japan, South Korea, China, and Taiwan navigating complex trade dynamics. Japan and South Korea are enhancing domestic pharmaceutical capabilities to mitigate reliance on imports, while China accelerates its biopharmaceutical innovation amidst export restrictions. Taiwan, pivotal in biotech manufacturing, faces geopolitical vulnerabilities due to US-China strife. The parent market - global rare disease therapeutics - demonstrates robust growth, driven by increasing prevalence and awareness. By 2035, market evolution will hinge on strategic alliances and innovation in treatment modalities. Concurrently, Middle East conflicts exacerbate global supply chain disruptions and energy price volatility, influencing manufacturing costs and logistics. These factors necessitate resilient strategies and diversified supply sources to sustain market momentum.

Key Trends and Drivers:

The Vaso Occlusive Crisis (VOC) market is experiencing growth due to advancements in therapeutic options and increased awareness of sickle cell disease. One key trend is the development of novel pharmaceuticals targeting the underlying causes of VOC, offering improved efficacy and patient outcomes. The integration of gene therapy represents another significant trend, providing potential long-term solutions to VOC management. Additionally, the expansion of telemedicine and digital health platforms is enhancing patient access to care and monitoring, thus improving disease management. Drivers include a growing prevalence of sickle cell disease globally, particularly in regions with high genetic predisposition. Enhanced diagnostic capabilities and early screening programs are also contributing to market growth by facilitating timely intervention and treatment. The push for personalized medicine is fostering the development of tailored treatment plans, which are proving to be more effective in managing VOC. Opportunities abound in emerging markets where healthcare infrastructure is evolving, offering potential for market expansion. Companies investing in innovative therapies and digital health solutions are well-positioned to capture market share. The VOC market is poised for growth as stakeholders focus on improving patient quality of life and reducing healthcare costs associated with crisis management.

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Device
• 2.8 Key Market Highlights by Process
• 2.9 Key Market Highlights by Solution

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Acute
  • 4.1.2 Chronic
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Pharmaceuticals
  • 4.2.2 Biologics
  • 4.2.3 Analgesics
  • 4.2.4 Hydroxyurea
  • 4.2.5 L-Glutamine
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Patient Support Services
  • 4.3.2 Consultation Services
  • 4.3.3 Telemedicine
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Gene Therapy
  • 4.4.2 CRISPR Technology
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Pain Management
  • 4.5.2 Blood Transfusion
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Hospitals
  • 4.6.2 Specialty Clinics
  • 4.6.3 Homecare Settings
• 4.7 Market Size & Forecast by Device (2020-2035)
  • 4.7.1 Infusion Pumps
  • 4.7.2 Pain Management Devices
• 4.8 Market Size & Forecast by Process (2020-2035)
  • 4.8.1 Diagnosis
  • 4.8.2 Treatment
  • 4.8.3 Monitoring
• 4.9 Market Size & Forecast by Solution (2020-2035)
  • 4.9.1 Integrated Care Solutions
  • 4.9.2 Patient Monitoring Solutions

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Device
    • 5.2.1.8 Process
    • 5.2.1.9 Solution
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Device
    • 5.2.2.8 Process
    • 5.2.2.9 Solution
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Device
    • 5.2.3.8 Process
    • 5.2.3.9 Solution
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Device
    • 5.3.1.8 Process
    • 5.3.1.9 Solution
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Device
    • 5.3.2.8 Process
    • 5.3.2.9 Solution
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Device
    • 5.3.3.8 Process
    • 5.3.3.9 Solution
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Device
    • 5.4.1.8 Process
    • 5.4.1.9 Solution
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Device
    • 5.4.2.8 Process
    • 5.4.2.9 Solution
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Device
    • 5.4.3.8 Process
    • 5.4.3.9 Solution
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Device
    • 5.4.4.8 Process
    • 5.4.4.9 Solution
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Device
    • 5.4.5.8 Process
    • 5.4.5.9 Solution
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Device
    • 5.4.6.8 Process
    • 5.4.6.9 Solution
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Device
    • 5.4.7.8 Process
    • 5.4.7.9 Solution
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Device
    • 5.5.1.8 Process
    • 5.5.1.9 Solution
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Device
    • 5.5.2.8 Process
    • 5.5.2.9 Solution
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Device
    • 5.5.3.8 Process
    • 5.5.3.9 Solution
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Device
    • 5.5.4.8 Process
    • 5.5.4.9 Solution
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Device
    • 5.5.5.8 Process
    • 5.5.5.9 Solution
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Device
    • 5.5.6.8 Process
    • 5.5.6.9 Solution
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Device
    • 5.6.1.8 Process
    • 5.6.1.9 Solution
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Device
    • 5.6.2.8 Process
    • 5.6.2.9 Solution
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Device
    • 5.6.3.8 Process
    • 5.6.3.9 Solution
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Device
    • 5.6.4.8 Process
    • 5.6.4.9 Solution
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 End User
    • 5.6.5.7 Device
    • 5.6.5.8 Process
    • 5.6.5.9 Solution

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Global Blood Therapeutics
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Emmaus Life Sciences
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Imara
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Forma Therapeutics
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Sancilio Pharmaceuticals
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Hema Care
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Glyco Mimetics
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Sickle Cell Disease Association of America
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Ar Qule
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Bioverativ
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 CRISPR Therapeutics
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Editas Medicine
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Sangamo Therapeutics
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Bluebird Bio
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Novartis Institutes for Bio Medical Research
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Pfizer Rare Disease Consortium
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Mast Therapeutics
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Celgene Cellular Therapeutics
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Voyager Therapeutics
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Astraea Therapeutics
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us